| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Eclampsia | 81 | 2025 | 268 | 24.680 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 57 | 2025 | 105 | 14.700 |
Why?
|
| Hypertension, Pregnancy-Induced | 25 | 2025 | 85 | 12.470 |
Why?
|
| Placenta Growth Factor | 41 | 2025 | 81 | 9.780 |
Why?
|
| Pregnancy | 125 | 2025 | 3240 | 7.570 |
Why?
|
| Hypertension | 15 | 2025 | 774 | 5.470 |
Why?
|
| Biomarkers | 46 | 2025 | 1930 | 4.440 |
Why?
|
| Postpartum Period | 17 | 2025 | 163 | 4.170 |
Why?
|
| Blood Pressure | 16 | 2025 | 926 | 4.020 |
Why?
|
| Pregnancy Proteins | 18 | 2015 | 37 | 3.900 |
Why?
|
| Placenta | 14 | 2025 | 191 | 3.860 |
Why?
|
| Premature Birth | 9 | 2023 | 130 | 3.290 |
Why?
|
| Antihypertensive Agents | 7 | 2024 | 264 | 2.480 |
Why?
|
| Female | 128 | 2025 | 50028 | 2.470 |
Why?
|
| Pregnancy Outcome | 17 | 2024 | 273 | 2.450 |
Why?
|
| Angiogenic Proteins | 7 | 2019 | 17 | 2.210 |
Why?
|
| Adult | 78 | 2025 | 28721 | 1.830 |
Why?
|
| Angiogenesis Inducing Agents | 8 | 2022 | 30 | 1.770 |
Why?
|
| Humans | 128 | 2025 | 96105 | 1.710 |
Why?
|
| Puerperal Disorders | 6 | 2025 | 37 | 1.680 |
Why?
|
| Infant, Newborn | 23 | 2025 | 2614 | 1.570 |
Why?
|
| Furosemide | 2 | 2025 | 33 | 1.560 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 4 | 2024 | 36 | 1.490 |
Why?
|
| Pregnancy Trimester, Third | 11 | 2020 | 71 | 1.480 |
Why?
|
| Prenatal Care | 5 | 2023 | 84 | 1.430 |
Why?
|
| Prenatal Diagnosis | 3 | 2019 | 110 | 1.370 |
Why?
|
| Patient Readmission | 6 | 2025 | 413 | 1.300 |
Why?
|
| Postnatal Care | 5 | 2024 | 31 | 1.270 |
Why?
|
| Retrospective Studies | 28 | 2024 | 10287 | 1.230 |
Why?
|
| Cesarean Section | 5 | 2025 | 157 | 1.190 |
Why?
|
| Prospective Studies | 20 | 2025 | 4671 | 1.170 |
Why?
|
| Pregnancy Complications, Cardiovascular | 5 | 2017 | 111 | 1.150 |
Why?
|
| Receptors, Cell Surface | 9 | 2015 | 298 | 1.120 |
Why?
|
| Placentation | 4 | 2020 | 11 | 1.120 |
Why?
|
| Antigens, CD | 9 | 2015 | 481 | 1.090 |
Why?
|
| Peripartum Period | 6 | 2024 | 29 | 1.060 |
Why?
|
| Gestational Age | 13 | 2025 | 343 | 1.030 |
Why?
|
| Obstetric Labor Complications | 2 | 2021 | 34 | 1.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 9 | 2024 | 403 | 0.990 |
Why?
|
| Cardiovascular Diseases | 5 | 2025 | 777 | 0.990 |
Why?
|
| Telemedicine | 4 | 2024 | 229 | 0.950 |
Why?
|
| Obstetric Labor, Premature | 2 | 2023 | 58 | 0.950 |
Why?
|
| Diuretics | 1 | 2025 | 77 | 0.870 |
Why?
|
| Cost Savings | 1 | 2025 | 71 | 0.870 |
Why?
|
| Abdominal Pain | 1 | 2025 | 145 | 0.820 |
Why?
|
| Risk Assessment | 9 | 2025 | 2480 | 0.790 |
Why?
|
| Fetal Growth Retardation | 2 | 2021 | 72 | 0.780 |
Why?
|
| United States | 15 | 2025 | 7768 | 0.770 |
Why?
|
| Activins | 3 | 2021 | 26 | 0.760 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2023 | 127 | 0.750 |
Why?
|
| Case-Control Studies | 13 | 2021 | 1957 | 0.750 |
Why?
|
| Cardiomyopathies | 6 | 2024 | 286 | 0.750 |
Why?
|
| Pregnancy Complications | 6 | 2017 | 356 | 0.750 |
Why?
|
| Young Adult | 29 | 2025 | 7025 | 0.730 |
Why?
|
| Birth Intervals | 1 | 2021 | 7 | 0.700 |
Why?
|
| Databases, Factual | 4 | 2024 | 1010 | 0.690 |
Why?
|
| Risk Factors | 19 | 2021 | 5961 | 0.680 |
Why?
|
| Patient Discharge | 1 | 2024 | 361 | 0.670 |
Why?
|
| Severity of Illness Index | 6 | 2024 | 1979 | 0.670 |
Why?
|
| Patient Satisfaction | 1 | 2024 | 514 | 0.670 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 662 | 0.660 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 647 | 0.660 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 569 | 0.650 |
Why?
|
| Racism | 1 | 2022 | 105 | 0.640 |
Why?
|
| Patient Compliance | 1 | 2021 | 239 | 0.640 |
Why?
|
| Trophoblasts | 5 | 2023 | 36 | 0.620 |
Why?
|
| Prevalence | 5 | 2024 | 1349 | 0.620 |
Why?
|
| Neovascularization, Physiologic | 5 | 2024 | 142 | 0.620 |
Why?
|
| Pregnancy Trimester, Second | 8 | 2019 | 71 | 0.600 |
Why?
|
| Luteolin | 3 | 2023 | 4 | 0.580 |
Why?
|
| Endoglin | 10 | 2017 | 21 | 0.570 |
Why?
|
| Heart Ventricles | 3 | 2021 | 810 | 0.570 |
Why?
|
| Chicago | 6 | 2024 | 1506 | 0.550 |
Why?
|
| Predictive Value of Tests | 9 | 2024 | 1805 | 0.550 |
Why?
|
| Hydrops Fetalis | 2 | 2020 | 17 | 0.530 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2018 | 340 | 0.530 |
Why?
|
| Birth Weight | 5 | 2020 | 152 | 0.510 |
Why?
|
| Cohort Studies | 9 | 2024 | 3110 | 0.500 |
Why?
|
| Tertiary Care Centers | 3 | 2021 | 128 | 0.480 |
Why?
|
| Obesity | 2 | 2020 | 1030 | 0.460 |
Why?
|
| Placental Insufficiency | 1 | 2014 | 4 | 0.440 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2014 | 33 | 0.430 |
Why?
|
| Ouabain | 1 | 2014 | 25 | 0.430 |
Why?
|
| HELLP Syndrome | 2 | 2013 | 8 | 0.430 |
Why?
|
| Diagnosis, Differential | 6 | 2025 | 1619 | 0.430 |
Why?
|
| Placenta Diseases | 3 | 2021 | 13 | 0.420 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 2012 | 14 | 0.420 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 95 | 0.410 |
Why?
|
| Pregnancy Trimester, First | 4 | 2015 | 63 | 0.390 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 170 | 0.390 |
Why?
|
| Blood Pressure Determination | 2 | 2024 | 69 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2012 | 25 | 0.380 |
Why?
|
| Pregnancy, Twin | 1 | 2012 | 8 | 0.380 |
Why?
|
| Prognosis | 7 | 2021 | 4028 | 0.380 |
Why?
|
| Fetal Death | 3 | 2020 | 57 | 0.380 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 62 | 0.380 |
Why?
|
| Lymphangiogenesis | 1 | 2012 | 41 | 0.370 |
Why?
|
| Maternal Serum Screening Tests | 1 | 2012 | 1 | 0.370 |
Why?
|
| Perinatology | 1 | 2012 | 15 | 0.370 |
Why?
|
| Eclampsia | 1 | 2012 | 24 | 0.370 |
Why?
|
| Pilot Projects | 4 | 2020 | 938 | 0.340 |
Why?
|
| Health Care Costs | 2 | 2024 | 255 | 0.340 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 3927 | 0.330 |
Why?
|
| Fetal Diseases | 2 | 2010 | 81 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 2 | 2025 | 501 | 0.330 |
Why?
|
| Maternal Mortality | 2 | 2022 | 15 | 0.320 |
Why?
|
| Heart Diseases | 2 | 2024 | 314 | 0.310 |
Why?
|
| Infant, Low Birth Weight | 2 | 2020 | 62 | 0.310 |
Why?
|
| Cervix Uteri | 1 | 2010 | 73 | 0.310 |
Why?
|
| Patient Education as Topic | 2 | 2024 | 378 | 0.310 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 191 | 0.300 |
Why?
|
| Quality Improvement | 2 | 2024 | 502 | 0.290 |
Why?
|
| Vagina | 1 | 2010 | 181 | 0.290 |
Why?
|
| Clinical Competence | 2 | 2012 | 854 | 0.280 |
Why?
|
| Urban Population | 2 | 2019 | 240 | 0.280 |
Why?
|
| Epilepsy | 1 | 2012 | 451 | 0.270 |
Why?
|
| Follistatin-Related Proteins | 2 | 2025 | 11 | 0.270 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2017 | 155 | 0.260 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 682 | 0.260 |
Why?
|
| Cooking | 2 | 2017 | 70 | 0.250 |
Why?
|
| Chronic Disease | 2 | 2020 | 983 | 0.250 |
Why?
|
| Haiti | 2 | 2017 | 22 | 0.250 |
Why?
|
| Hospitalization | 2 | 2024 | 943 | 0.250 |
Why?
|
| Immunoassay | 3 | 2025 | 100 | 0.250 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2013 | 299 | 0.240 |
Why?
|
| Delivery, Obstetric | 2 | 2023 | 124 | 0.240 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 155 | 0.240 |
Why?
|
| Fetal Distress | 1 | 2025 | 11 | 0.230 |
Why?
|
| Risk | 3 | 2018 | 668 | 0.230 |
Why?
|
| Decision Trees | 1 | 2025 | 63 | 0.220 |
Why?
|
| Physicians | 1 | 2012 | 707 | 0.220 |
Why?
|
| Pregnancy in Diabetics | 2 | 2015 | 41 | 0.220 |
Why?
|
| Echocardiography | 4 | 2021 | 1004 | 0.210 |
Why?
|
| Ovariectomy | 1 | 2004 | 91 | 0.210 |
Why?
|
| Fallopian Tubes | 1 | 2004 | 49 | 0.210 |
Why?
|
| Text Messaging | 1 | 2024 | 35 | 0.210 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2860 | 0.200 |
Why?
|
| Length of Stay | 2 | 2018 | 833 | 0.200 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 137 | 0.200 |
Why?
|
| Administration, Oral | 1 | 2025 | 688 | 0.200 |
Why?
|
| Labor, Obstetric | 1 | 2023 | 48 | 0.190 |
Why?
|
| Tissue Culture Techniques | 2 | 2020 | 81 | 0.190 |
Why?
|
| Oxidative Stress | 2 | 2019 | 473 | 0.190 |
Why?
|
| Perception | 1 | 2023 | 185 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2023 | 159 | 0.190 |
Why?
|
| Diabetes, Gestational | 2 | 2015 | 49 | 0.180 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2021 | 2 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 3 | 2013 | 354 | 0.180 |
Why?
|
| Income | 1 | 2022 | 90 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 367 | 0.180 |
Why?
|
| Morbidity | 2 | 2019 | 160 | 0.170 |
Why?
|
| Aspirin | 2 | 2020 | 169 | 0.170 |
Why?
|
| Stroke Volume | 2 | 2016 | 531 | 0.170 |
Why?
|
| Cognition | 1 | 2006 | 635 | 0.170 |
Why?
|
| Heart Failure | 2 | 2024 | 1422 | 0.170 |
Why?
|
| Evidence-Based Practice | 1 | 2021 | 51 | 0.170 |
Why?
|
| Recurrence | 2 | 2021 | 1218 | 0.170 |
Why?
|
| Attitude | 1 | 2022 | 137 | 0.170 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 517 | 0.170 |
Why?
|
| Uterine Artery | 1 | 2020 | 6 | 0.170 |
Why?
|
| Fetofetal Transfusion | 1 | 2020 | 8 | 0.170 |
Why?
|
| Maternal Health Services | 2 | 2017 | 16 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2023 | 477 | 0.170 |
Why?
|
| NF-kappa B | 1 | 2023 | 469 | 0.160 |
Why?
|
| Endometrium | 1 | 2020 | 52 | 0.160 |
Why?
|
| Vasodilation | 1 | 2020 | 96 | 0.160 |
Why?
|
| Membrane Proteins | 3 | 2013 | 1276 | 0.160 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2020 | 47 | 0.160 |
Why?
|
| Fibrin | 1 | 2020 | 87 | 0.160 |
Why?
|
| India | 1 | 2020 | 138 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 713 | 0.160 |
Why?
|
| Betamethasone | 1 | 2019 | 5 | 0.160 |
Why?
|
| Fetal Organ Maturity | 1 | 2019 | 4 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 140 | 0.160 |
Why?
|
| Urban Health | 1 | 2020 | 55 | 0.160 |
Why?
|
| Organoids | 1 | 2020 | 78 | 0.160 |
Why?
|
| Myocardial Contraction | 1 | 2021 | 253 | 0.160 |
Why?
|
| Myxoma | 1 | 2019 | 31 | 0.150 |
Why?
|
| Drug Utilization | 1 | 2019 | 69 | 0.150 |
Why?
|
| Health Personnel | 1 | 2021 | 241 | 0.150 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 65 | 0.150 |
Why?
|
| Poverty | 1 | 2020 | 196 | 0.150 |
Why?
|
| Medical Records | 1 | 2019 | 126 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2020 | 713 | 0.150 |
Why?
|
| Time Factors | 4 | 2021 | 5580 | 0.140 |
Why?
|
| China | 1 | 2019 | 264 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2021 | 221 | 0.140 |
Why?
|
| ROC Curve | 3 | 2024 | 797 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 190 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2020 | 740 | 0.140 |
Why?
|
| Infant, Premature | 1 | 2020 | 308 | 0.140 |
Why?
|
| Inflammation | 1 | 2023 | 1063 | 0.130 |
Why?
|
| Parity | 3 | 2013 | 97 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2019 | 369 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 801 | 0.130 |
Why?
|
| Maternal Death | 1 | 2017 | 3 | 0.130 |
Why?
|
| Triage | 1 | 2018 | 132 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 380 | 0.130 |
Why?
|
| Maternal Exposure | 1 | 2017 | 63 | 0.130 |
Why?
|
| Air Pollution, Indoor | 1 | 2017 | 80 | 0.130 |
Why?
|
| Gelsolin | 1 | 2016 | 11 | 0.130 |
Why?
|
| Chorionic Villi | 1 | 2016 | 11 | 0.120 |
Why?
|
| Rural Population | 1 | 2017 | 171 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 491 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2020 | 1267 | 0.120 |
Why?
|
| Relaxin | 1 | 2016 | 9 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2019 | 815 | 0.120 |
Why?
|
| Heart | 2 | 2017 | 591 | 0.120 |
Why?
|
| Prolactin | 1 | 2016 | 89 | 0.120 |
Why?
|
| Animals | 6 | 2024 | 28891 | 0.120 |
Why?
|
| Air Pollution | 1 | 2017 | 107 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 880 | 0.120 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 18 | 0.120 |
Why?
|
| Extracellular Vesicles | 1 | 2016 | 46 | 0.120 |
Why?
|
| Transcriptome | 1 | 2020 | 769 | 0.110 |
Why?
|
| Survival Rate | 1 | 2019 | 1985 | 0.110 |
Why?
|
| Shock, Cardiogenic | 1 | 2016 | 172 | 0.110 |
Why?
|
| Cardenolides | 1 | 2014 | 1 | 0.110 |
Why?
|
| Digitoxin | 1 | 2014 | 3 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 1034 | 0.110 |
Why?
|
| Infant | 1 | 2021 | 3363 | 0.110 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2011 | 37 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 2642 | 0.100 |
Why?
|
| Fetal Macrosomia | 2 | 2011 | 10 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 883 | 0.100 |
Why?
|
| Boston | 1 | 2013 | 39 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2039 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2015 | 235 | 0.100 |
Why?
|
| Lung | 1 | 2019 | 1384 | 0.100 |
Why?
|
| Adolescent | 7 | 2018 | 9895 | 0.100 |
Why?
|
| Rats | 2 | 2020 | 4155 | 0.090 |
Why?
|
| Hypoxia | 1 | 2017 | 681 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 622 | 0.090 |
Why?
|
| Pulmonary Edema | 1 | 2012 | 54 | 0.090 |
Why?
|
| Aneuploidy | 1 | 2012 | 64 | 0.090 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 13 | 0.090 |
Why?
|
| Directive Counseling | 1 | 2012 | 35 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2939 | 0.090 |
Why?
|
| Systole | 1 | 2012 | 116 | 0.090 |
Why?
|
| Neural Tube Defects | 1 | 2012 | 46 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2014 | 1157 | 0.090 |
Why?
|
| Health Care Surveys | 1 | 2012 | 295 | 0.090 |
Why?
|
| Chromosome Disorders | 1 | 2011 | 112 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2014 | 2090 | 0.080 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2010 | 7 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2011 | 133 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1973 | 0.080 |
Why?
|
| Logistic Models | 2 | 2012 | 1268 | 0.080 |
Why?
|
| Rupture, Spontaneous | 1 | 2010 | 43 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2020 | 9175 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 258 | 0.080 |
Why?
|
| fas Receptor | 1 | 2010 | 76 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 232 | 0.080 |
Why?
|
| Life Style | 1 | 2010 | 186 | 0.080 |
Why?
|
| Gynecology | 1 | 2011 | 130 | 0.070 |
Why?
|
| Obstetrics | 1 | 2011 | 123 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2012 | 565 | 0.070 |
Why?
|
| Twins | 1 | 2009 | 65 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 2880 | 0.070 |
Why?
|
| Abruptio Placentae | 1 | 2008 | 13 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 303 | 0.070 |
Why?
|
| Vitamin D | 1 | 2010 | 273 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 340 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2011 | 371 | 0.060 |
Why?
|
| Nigeria | 2 | 2017 | 162 | 0.060 |
Why?
|
| Smoking | 1 | 2010 | 653 | 0.060 |
Why?
|
| Tocolytic Agents | 1 | 2006 | 8 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1876 | 0.060 |
Why?
|
| Magnesium Sulfate | 1 | 2006 | 16 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 453 | 0.060 |
Why?
|
| Proteinuria | 2 | 2021 | 69 | 0.060 |
Why?
|
| Male | 5 | 2022 | 45863 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2007 | 175 | 0.060 |
Why?
|
| Fetal Weight | 1 | 2005 | 16 | 0.060 |
Why?
|
| Cheek | 1 | 2005 | 21 | 0.060 |
Why?
|
| Ethanol | 2 | 2017 | 270 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2008 | 364 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2591 | 0.050 |
Why?
|
| Vinblastine | 1 | 2004 | 100 | 0.050 |
Why?
|
| Reference Values | 1 | 2025 | 674 | 0.050 |
Why?
|
| Bleomycin | 1 | 2004 | 103 | 0.050 |
Why?
|
| Memory | 1 | 2006 | 229 | 0.050 |
Why?
|
| Etoposide | 1 | 2004 | 212 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1010 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 313 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2004 | 304 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3581 | 0.050 |
Why?
|
| Cisplatin | 1 | 2004 | 611 | 0.050 |
Why?
|
| Attention | 1 | 2006 | 413 | 0.040 |
Why?
|
| Gravidity | 1 | 2021 | 7 | 0.040 |
Why?
|
| American Heart Association | 1 | 2021 | 110 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2023 | 290 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2024 | 1730 | 0.040 |
Why?
|
| Decidua | 1 | 2020 | 22 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 305 | 0.040 |
Why?
|
| Follistatin | 1 | 2020 | 7 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 1773 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2020 | 152 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2777 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 370 | 0.040 |
Why?
|
| Aorta | 1 | 2020 | 294 | 0.040 |
Why?
|
| Algorithms | 1 | 2007 | 2015 | 0.040 |
Why?
|
| Incidence | 2 | 2016 | 1715 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 2086 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 873 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 526 | 0.040 |
Why?
|
| Exercise | 1 | 2021 | 354 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2018 | 21 | 0.030 |
Why?
|
| Automation, Laboratory | 1 | 2018 | 12 | 0.030 |
Why?
|
| Heart Atria | 1 | 2019 | 290 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2021 | 644 | 0.030 |
Why?
|
| Chromatin | 1 | 2020 | 450 | 0.030 |
Why?
|
| Perinatal Care | 1 | 2017 | 23 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2017 | 96 | 0.030 |
Why?
|
| Equipment Design | 1 | 2018 | 427 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 49 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 483 | 0.030 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2015 | 10 | 0.030 |
Why?
|
| Pregnancy, High-Risk | 1 | 2015 | 16 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2016 | 510 | 0.030 |
Why?
|
| Mice | 2 | 2024 | 12537 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1011 | 0.030 |
Why?
|
| Heparin | 1 | 2015 | 186 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2578 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 348 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1546 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 249 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1765 | 0.020 |
Why?
|
| Bromocriptine | 1 | 2012 | 12 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2012 | 18 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2015 | 463 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2012 | 128 | 0.020 |
Why?
|
| Trisomy 13 Syndrome | 1 | 2011 | 1 | 0.020 |
Why?
|
| Middle Aged | 3 | 2017 | 28368 | 0.020 |
Why?
|
| Vitamin E | 1 | 2011 | 34 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 2011 | 40 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2011 | 47 | 0.020 |
Why?
|
| Free Radicals | 1 | 2011 | 71 | 0.020 |
Why?
|
| Trisomy | 1 | 2011 | 56 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2011 | 51 | 0.020 |
Why?
|
| Pregnancy, Ectopic | 1 | 2011 | 37 | 0.020 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2011 | 91 | 0.020 |
Why?
|
| Anthropometry | 1 | 2010 | 78 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 446 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2012 | 323 | 0.020 |
Why?
|
| Pregnancy, Multiple | 1 | 2009 | 37 | 0.020 |
Why?
|
| Massachusetts | 1 | 2009 | 35 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 908 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 595 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 640 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2161 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 935 | 0.020 |
Why?
|
| Creatinine | 1 | 2007 | 299 | 0.020 |
Why?
|
| Dystocia | 1 | 2005 | 2 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1230 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2534 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 363 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 1963 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 365 | 0.010 |
Why?
|
| Child | 1 | 2012 | 7625 | 0.010 |
Why?
|